Morgan Stanley downgraded Treace Medical to Equal Weight from Overweight with a price target of $5.50, down from $15. Competitive disruptions are hitting Treace’s commercial momentum and the company is “now playing innovation catch up,” says the firm, which is lowering its outlook for future growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI: